Impact of Gut Microbiota and Tryptophan Metabolites on Acute Pain in Lumbar Disc Herniation Surgery Patients

Dokuz Eylül University (DEU)

Status: Completed

Conditions: Postoperative Pain, Acute; Microbial Substitution; Tryptophan Metabolism Alterations

Treatments: Procedure: Pain Perception in Patients Undergoing Lumbar Disc Herniation Surgery

Study type: Observational

Funder types: Other

Identifiers

NCT06502223

DEU-Çelik001

Details and patient eligibility

About

It is well-established that the gut microbiota plays a crucial role in various pain mechanisms, including visceral pain, inflammatory pain, headache, neuropathic pain, and opioid tolerance. Changes in the gut microbiome can alter pain perception. In our study, The investigator investigated the effects of microbiota alterations and the associated tryptophan metabolites on acute pain using the Visual Analog Scale (VAS).

Full description

The study included patients aged 18 and above undergoing lumbar disc herniation surgery. Blood samples were collected preoperatively, at 8 hours, and at 24 hours postoperatively to analyze tryptophan metabolites (picolinic acid, 3- Hydroxykynurenine, anthranilic acid, kynurenine, quinolinic acid, kynurenic acid, xanthurenic acid). Concurrent VAS pain assessments were conducted, and correlations between tryptophan metabolites and VAS were evaluated.

Enrollment: 37 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients undergoing lumbar disc herniation surgery at Dokuz Eylül University Hospital.
• Patients who have read and consented to the informed consent form for the study.
• Age 18 years or older.
• Surgery duration exceeding 2 hours.

Exclusion criteria

• Patients are unwilling to participate in the study.
• Surgery duration less than 2 hours.
• Patients under the age of 18.
• Patients with a history of abdominal surgery.
• Patients who received antibiotic therapy for intestinal pathology within the last 3 weeks.
• Patients with known abdominal pathologies suspected to alter the microbial flora (e.g., Crohn's disease, ulcerative colitis, celiac disease).

Trial design